Status: Not yet recruiting
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).
Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.Updated: Jul 24, 2026Locations: 11
Eligibility criteria
Participant must be 18 years of age or older at the time of signing informed con... [+27]
Current or previous evidence of muscle invasive, locally advanced nonresectable,... [+12]